MANNKIND CORP Loans Assumed
MANNKIND CORP (MNKD) reported Loans Assumed of $5.17 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LoansAssumed1 · last filed 2019-02-26
- MANNKIND CORP loans assumed for the quarter ending 2016-12-31 was $461.00K, a 98.52% decline year-over-year.
- MANNKIND CORP loans assumed for the quarter ending 2016-09-30 was -$290.00K.
- MANNKIND CORP loans assumed for the quarter ending 2015-12-31 was $31.19M.
- MANNKIND CORP loans assumed for fiscal 2016 was $5.17M, a 91.28% decline from fiscal 2015.
- MANNKIND CORP loans assumed for fiscal 2015 was $59.34M, a 1855.74% increase from fiscal 2014.
- MANNKIND CORP loans assumed for fiscal 2014 was $3.03M.
| Period end | Loans Assumed 3 month | Loans Assumed 6 month | Loans Assumed 9 month | Loans Assumed 12 month |
|---|---|---|---|---|
| 2016-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $171.00K derived: sum of 2 quarters · filed 2019-02-26 | $5.17M 10-K · filed 2019-02-26 | |
| 2016-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $4.71M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $5.00M 10-Q · filed 2017-08-07 | |||
| 2015-12-31 | $31.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $59.34M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $28.15M 10-Q · filed 2016-11-09 | |||
| 2014-12-31 | $3.03M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |